Can nail brittleness be an adverse effect of Elexacaftor/Tezacaftor/Ivacaftor?
Argyri Petrocheilou*; Georgios Zarafonitis; Ioanna Loukou
Recent advances in cystic fibrosis therapeutics have resulted in the development of CFTR modulators that have led to great improvements in CF care. Novel adverse effects are still being reported. A case of brittle nails that were reported after initiation of treatment with Elexacaftor/Tezacaftor/Ivacaftor (ETI) is presented here. The parents have provided informed consent for this case presentation.